Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CNTX Context Therapeutics
1.110+0.427+62.52%
Trading Session
01/31 12:43 ET
High
1.550
Open
1.220
Turnover
79.88M
Low
1.060
Pre Close
0.683
Volume
66.09M
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Context Therapeutics Shares Halted On Circuit Breaker To Upside
Context Therapeutics Shares Halted On Circuit Breaker To Upside
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
09:09 AM EST, 01/31/2023 (MT Newswires) -- Health care stocks were mixed pre-bell Tuesday. The Health Care Select Sector SPDR Fund (XLV) was climbing by 0.4% and the iShares Biotechnology ETF (IBB) wa
Context Stock Soars ~70% as Trial Partner Stemline's Breast Cancer Drug Gets FDA Approval
Context Therapeutics' Clinical Partner Stemline Therapeutics Receives FDA Approval Of ORSERDU
Context Therapeutics' Clinical Partner Stemline Therapeutics Receives FDA Approval Of ORSERDU
Context Announces Stemline Received Approval From U.S. FDA for ORSERDU
$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying
The Nasdaq dropped more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in p
Context Therapeutics Says On Jan. 24 Co. Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Context Therapeutics Says On Jan. 24 Co. Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update
Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) was the target of a significant drop in short interest in the month of December. As of December 30th, there was short interest totalling 78,000 sh
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders i
Company Overview
More
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
CEO： Mr. Martin Lehr
Market： NASDAQ
Listing Date： 10/20/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet